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Cell Stress Induced by the Parkinsonian Mimetic,
6-Hydroxydopamine, is Concurrent with Oxidation of
the Chaperone, ERp57, and Aggresome Formation
JEONG SOOK KIM-HAN and KAREN L. O’MALLEY

ABSTRACT
Parkinson’s disease (PD) involves an irreversible degeneration of the nigrostriatal pathway. As most cases of
PD are sporadic, environmental risk factors may underlie neurodegeneration in dopaminergic neurons. One
such factor is 6-hydroxydopamine (6-OHDA), which is widely used as a parkinsonian mimetic. Studies have
shown that 6-OHDA generates reactive oxygen species and induces cell stress, the unfolded protein response,
and apoptosis. Present findings show that 6-OHDA, but not hydrogen peroxide, MPP, or rotenone, leads to
the rapid formation of high-molecular-weight species of protein disulfide isomerase–associated protein 3
(ERp57) in a dose- and time-dependent fashion. Moreover, ERp57 conjugates are blocked by N-acetylcysteine
and glutathione, suggesting that they represent oxidized forms of protein. Surprisingly, conjugates are complexed with DNA, because treatment with DNase reduces their appearance. Subcellular fractionation indicates that both nuclear and mitochondrial DNA are associated with the protein. Finally, toxin-treated ERp57
rapidly forms juxtanuclear aggresome-like structures in dopaminergic cells, suggesting that ERp57 plays an
early adaptive response in toxin-mediated stress. Understanding the signaling mechanisms associated with
parkinsonian mimetics, as well as their temporal induction, may aid in designing better interventions in models of PD. Antioxid. Redox Signal. 9, 2255–2264.

INTRODUCTION

N

that cellular stress systems are
involved in a variety of neurodegenerative disorders such
as Alzheimer’s disease, Parkinson’s disease (PD), and prionrelated disorders. In particular, genetic mutations linked to PD,
such as -synuclein, parkin, UCH-L1, and LRRK2, have highlighted the role of aberrant protein degradation in this disorder
(11). Accumulation of protein aggregates within the cell can
trigger stress-activated signaling pathways, particularly in the
endoplasmic reticulum (ER), which in turn activate adaptive responses such as the unfolded protein response (UPR). The UPRmediated recovery from ER stress uses both protein translation
and gene transcription to overcome abnormal protein alterUMEROUS STUDIES SUGGEST

ations. Prolonged cell stress, however, overwhelms these processes, and apoptosis is initiated (43). Previous results from this
laboratory (13–15), as well as others (e.g., 36), demonstrated a
link between PD-associated genetic and environmental factors
with the discovery that the widely used parkinsonian mimetic,
6-hydroxydopamine (6-OHDA) induces the upregulation of
genes involved in the ER stress response. Mechanistically, 6OHDA–induced reactive oxygen species (ROS) lead to the
rapid formation of oxidized, carbonylated proteins that precede
UPR upregulation (14).
Evidence suggests that carbonylation is a common indicator
of oxidative damage in aging and in neurodegenerative disorders, such as PD (32). In general, however, only subsets of proteins have been shown to be carbonylated, such as chaperones,
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cytoskeletal proteins, protein disulfide isomerases (PDIs), and
various metabolic enzymes (1, 5, 7, 34). Oxidation of these
proteins, many of which are cell protective, may trigger
downstream events such as UPR and apoptosis. Previously,
we reported that one such carbonylation-prone protein, PDIassociated protein 3 (ERp57; Genebank MGI:95834), was upregulated by 6-OHDA (13).
ERp57 (or GRP58) was first reported as a glucose-regulated
protein/chaperone along with other cell-stress proteins like
GRP78(BIP) and GRP94 (23, 26). Largely localized in the ER
lumen, ERp57 not only plays a role as a chaperone but it also
functions as a disulfide reductase, a disulfide isomerase, and a
dithiol oxidase (10). Recently, ERp57 was shown to be upregulated after prion replication in a murine scrapie model, in
which it appeared to serve a neuroprotectant role (12). As
scrapie and other transmissible spongiform encephalopathies
are characterized by the accumulation of abnormally folded
prion protein, these data suggest that ERp57 somehow plays a
role in abrogating these processes. Whether ERp57 blocks some
step in this process or helps to prevent prion aggregation in the
first place (or both) is unclear.
One early step in protein aggregation is the formation of socalled aggresomes. These clusters of aggregated proteins are
retrogradely transported on microtubules to juxtanuclear regions where they can be degraded by autophagy (21). Typically, aggresomes are enriched in chaperones, 19S and 26S proteasome subunits, intermediate filament proteins, and ubiquitin
(21). Although autophagic vesicles are considered a cellular defense mechanism, they can lead to cell death by interfering with
normal cellular trafficking or by incomplete degradation of aggregated material. The latter may overwhelm the ubiquitin–proteosome system, triggering ER stress, UPR, and apoptosis. (31).
Thus, emerging studies suggest links between ER stress, protein aggregation, and autophagy (16, 29, 35). These findings,
together with the upregulation of ERp57 in dopaminergic cells
after toxin treatment, prompted us to test the hypothesis that
ERp57 plays a role in 6-OHDA–mediated UPR induction. Here
we show that toxin-treated dopaminergic cells lead to the rapid
appearance of DNA-containing high-molecular-weight conjugates of ERp57 as well as aggresome formation. These data
suggest that ERp57 plays an early adaptive response in 6OHDA–mediated toxicity.

sues were trypsinized in the presence of 0.05% DNase and triturated by using a Pasteur pipette. Dissociated cells (1.5  106
cells/cm2) were plated on the 0.5-mg/ml poly-D-lysine and 2.5
g/ml laminin (BD Bioscience, San Jose, CA) precoated culture dishes. Cultures were used 7–9 days after plating.
MN9D cells, an immortalized murine mesencephalic dopaminergic cell line (4), were plated on 0.1 mg/ml poly-D-lysine precoated plates and maintained in Iscove’s Dulbecco’s modified
Eagle’s medium with 10% fetal bovine serum in the presence
of 10% CO2 at 37°C. Medium was replaced with serum-free
Iscove’s Dulbecco’s modified Eagle’s medium/F12/B27 supplement 30 min before the addition of experimental agents.

Western blot analysis
After treatment, samples were washed twice with phosphatebuffered saline (PBS), lysed in RIPA buffer (50 mM Tris-HCl,
pH 7.5; 1% NP-40; 1% deoxycholate; 0.1% SDS; 150 mM
NaCl) and Complete protease inhibitor mixture and pelleted by
centrifugation. The supernatant was collected. Protein concentrations were measured by the BioRad Protein Assay Kit (Hercules, CA) by using bovine serum albumin as a control. Equal
amounts of protein were then run on 12% polyacrylamide gels
and transferred onto PVDF membranes (BioRad). After incubation in blocking buffer (20 mM Tris base, 150 mM NaCl, 5%
nonfat milk, and 0.1% Tween 20), membranes were incubated
with primary antibodies overnight at 4°C. ERp57 protein was
detected with a polyclonal rabbit anti-human ERp57 antibody
at a dilution of 1:2,000. Mouse monoclonal antibodies against
-actin (Sigma; 1:5,000), calnexin (BD Bioscience, San Jose,
CA; 1:250), cytochrome c (BD Pharmingen, San Diego, CA;
1:500), lamin B (Zymed, South San Francisco; 1:1,000), and
STAT3 (Cell Signaling, Danvers, MA; 1:1,000) were used.
After washes in the blocking buffer, membranes were incubated for 1 h with the appropriate anti-IgG secondary antibody
conjugated to horseradish peroxidase (Cell Signaling) diluted
1:3,000. After a second series of washes, bound antibody complexes were visualized by using the ECL plus Western Blotting
Detection System ECL (GE Healthcare, Buckinghamshire,
U.K.) and quantitative fluoroimaging (Storm 860; Global Medical Instrumentation, Inc., Ramsey, MN).

Immunocytochemistry
MATERIALS AND METHODS
Materials and reagents
Rabbit anti-ERp57 antibody was kindly provided by Dr.
Thomas Wileman (Institute for Animal Health, Surrey, U.K.).
RNase A and Complete protease inhibitor mixture were purchased from Roche (Mannheim, Germany). Unless otherwise
indicated, all other chemicals were from Sigma (St. Louis, MO).

Cell cultures
Murine primary mesencephalic neuronal cultures were prepared as described previously (25). In brief, the ventral mesencephalon was dissected from embryonic day 14 CF1 murine
embryos (Charles River Laboratories, Wilmington, MA). Tis-

After treatment, cells were rinsed twice with PBS, fixed with
4% paraformaldehyde in PBS for 30 min. Cells were doublestained with anti-ERp57 antibody (1:2,000) and cytochrome c
(Promega, Madison, WI; 1:4,000) or LAMP1 (Hybridoma
1D4B, Developmental Studies Hybridoma Bank, The University of Iowa, Iowa City, IA; 1:100) antibody, together with a
sheep polyclonal antibody against the dopaminergic neuronal
marker, tyrosine hydroxylase (Novus Biologicals, Littleton,
CO; 1:600). Mouse monoclonal antibodies against -tubulin
(Sigma; 1:10,000), and 8-hydroxyguanosine (QED Bioscience,
San Diego, CA; 1:100) were used. Secondary antibodies conjugated with Cy3 (anti-mouse and anti-rabbit, 1:300; Jackson
ImmunoResearch Laboratories, West Grove, PA) and Alexa
488 (anti-mouse, 1:500; anti-rabbit, 1:2,000; Molecular Probes,
Eugene, OR) were used. Cells were imaged by using an Olympus Fluoview confocal microscope.
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Treatment of lysates with DNase or RNase
Cell lysates were treated with 10 mg/ml DNaseI or 10 mg/ml
RNase or both in 10 mM Tris-HCl, pH 7.0, 2.5 mM MgCl2,
and 0.5 mM CaCl2 at 25°C for 1 h. Samples were subjected to
SDS-PAGE, followed by Western blot analysis.

Subcellular fractionation
Cells were rinsed and harvested in PBS and homogenized in
a sucrose buffer (0.32 M sucrose, 10 mM Tris-HCl, pH 7.2; 1
mM EDTA, pH 8.0) containing Complete protease inhibitors
by using an all-glass Dounce homogenizer. After centrifugation
at 800 g for 5 min, the supernatant was centrifuged at 10,000
g for 10 min. Pellets were collected for the mitochondrial fraction (M), and the supernatant was further centrifuged at 100,000
g for 1 h to obtain microsomal membranes (ER) and cytosol
(C). All fractions were resuspended in RIPA buffer and subjected to Western blot analysis.

Determination of redox state of ERp57 in vivo
The redox state of ERp57 in vivo was determined by sequential alkylation of free thiols with N-ethylmaleimide (NEM)
and 4-acetamido-4-maleimidylstilbene-2,2-disulfonic acid
(AMS), essentially as described by Jessop and Bulleid (19), but
with some minor modifications. In brief, cells were treated with
25 mM NEM for 20 min at 37°C, washed with ice-cold PBS,
and lysed in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM
EDTA, 1 Complete protease inhibitor mixture, and 1% Triton X-100. Cell lysates were treated with 2% SDS and 50 mM
DTT, precipitated with 10% trichloroacetic acid, washed with
ice-cold 70% acetone, and resuspended in 80 mM Tris, pH 6.8,

FIG. 1. 6-OHDA does not alter the ratio of
oxidized to reduced ERp57 in MN9D
cells. (A) Cells were treated as indicated before NEM alkylation and lysis. After an
overnight incubation with AMS, cell lysates
were subjected to gradient SDS-PAGE and
Western blotting with antibodies against
ERp57. Samples treated with DTT or DPS for
5 min before fixation were used to determine
the reduced and oxidized states of ERp57. (B)
Quantitation of results shown in (A). Values
represent mean  SEM, n  3.

2% SDS, and 1 Complete protease inhibitor mixture. Samples were incubated with 30 mM AMS overnight at 25°C followed by 20 min at 37°C. Samples were separated by
7.5–12.5% gradient SDS-PAGE and Western blotted to detect
ERp57. To determine the “all-oxidized” or “all-reduced” form
of ERp57, cells were treated with 5 mM dipyridyl sulfide (DPS)
or 10 mM dithiothreitol (DTT), respectively, for 5 min before
the addition of alkylating thiols.

RESULTS
ERp57 is partially oxidized in MN9D cells
Previously we showed that 6-OHDA rapidly induces ER
stress and UPR in MN9D and primary dopaminergic neurons
in a ROS-dependent fashion (13). As ERp57 was one of 21 proteins specifically upregulated by 6-OHDA (13) and because it
is readily oxidized (22), we tested the hypothesis that ERp57
is specifically oxidized by toxin treatment in MN9D cells. Cells
were treated with and without 6-OHDA for 3 h, after which cell
lysates were alkylated to determine the oxidation state of
ERp57. Although most reports describe ERp57 as primarily being reduced (20), equal amounts of oxidized and reduced forms
of ERp57 were observed in MN9D cells, even in nontreated
cells (Fig. 1A and B). Surprisingly, toxin treatment did not alter these ratios (Fig. 1A and B). Co-treatment with the thiol
antioxidant, N-acetyl-L-cysteine (NAC) significantly increased
the reduced form of ERp57, irrespective of the presence of 6OHDA. Therefore, ERp57 is already partially oxidized in nontreated, control MN9D cells.
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FIG. 2. 6-OHDA induces the formation of HMW conjugates of ERp57. MN9D cells were treated as indicated, and cell
lysates were prepared for Western blotting with anti-ERp57 antibodies. Time- (A) and dose (B)-dependent appearance of ERp57
HMW conjugates induced by 6-OHDA but not 1 mM H2O2. (C) Neither MPP nor rotenone (Rot) formed HMW conjugates 3
h after treatment, as indicated. Ctl, control.

6-OHDA treatment results in the rapid
formation of high-molecular-weight
conjugates of ERp57
Although 6-OHDA did not alter the oxidation state of
ERp57 in MN9D cells, Western blot analysis revealed the unexpected formation of high-molecular-weight (HMW) conjugates shortly after toxin treatment in MN9D cells (Fig. 2A).
Specifically, HMW conjugates were first visible at 1 h after
6-OHDA treatment, reaching a maximum at 3 h, and persisting for at least 12 h, the longest time point tested (Figs. 2A
and 3A). The formation of HMW conjugates was dose dependent (Fig. 2B) and specific for 6-OHDA, because other
compounds known to generate ROS, such as H2O2, MPP, or
rotenone never formed HMW species at any concentration
tested (Fig. 2A and C). To identify the location of HMW conjugation, subcellular fractionation was performed after treatment with 6-OHDA. Contrary to most reports, in MN9D cells,
ERp57 was highly expressed in the mitochondrial fraction
(Cox I positive fraction) versus ER membranes (P100; Fig.
3A) or the cytosol (S100; Fig. 3A). HMW conjugates were
enriched in the mitochondrial fractions at all times (Fig. 3A).
To determine whether the HMW conjugates represented
ERp57 covalent interactions stabilized by disulfide bridges,
lysates were treated with a reducing agent before size fractionation and Western blotting. Because no change in band in-

tensity was observed in the presence of the reducing agent
(Fig. 3B), it seems unlikely that the HMW species represent
ERp57 oligomers linked by disulfide bonds. Taken together,
these data indicate that the dopaminergic toxin, 6-OHDA, induces a specific change in ERp57 that leads to the rapid induction of HMW conjugates of unknown function.

Toxin-induced ERp57 HMW conjugates
contain DNA
To test whether the formation of HMW ERp57 conjugates
by 6-OHDA could be blocked by antioxidants, MN9D cells
were co-treated with NAC or glutathione in the presence of
toxin. NAC completely abolished the HMW ERp57 conjugates, whereas glutathione only partially blocked their appearance (Fig. 4A). To test whether the HMW ERp57 species
were complexes of known ERp57-interacting proteins, Western blots were probed with antibodies directed against the transcription factor, STAT3, or calnexin. No specific bands were
revealed, however, in the size range of the ERp57 HMW conjugates after 6-OHDA treatment (data not shown). Similarly,
treatment with deglycosylation agents such as PNGF did not
shift the size range of the HMW conjugates (Fig. 4B). Surprisingly, treatment of protein lysates with DNaseI significantly decreased the levels of 6-OHDA–generated HMW conjugates, whereas inclusion of RNase did not induce any

FIG. 3. Characterization of HMW conjugates of ERp57 induced by 6-OHDA. MN9D cell lysates after treatment, as indicated, were prepared for Western blotting with anti-ERp57 antibodies. (A) Subcellular fractionation of MN9D cells was performed to obtain mitochondrial (M), ER, and cytoplasmic (C) fractions from untreated cells or cells treated for 3, 6, 9, or 12 h
with 75 M 6-OHDA. Fractions were Western blotted with anti-CoxI and anti-LDH confirming compartmental designations as
well as anti-ERp57 to detect changes in localization. Results shown are representative of at least three independent experiments.
(B) HMW conjugates were not affected by the reducing agent, -mercaptoethanol (BME). Protein samples were treated with or
without BME before SDS-PAGE. Where indicated, -actin served as a loading control.
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FIG. 4. ERp57 HMW conjugates are complexed with DNA. (A) HMW conjugates can be blocked by cotreatment of antioxidants NAC (5 mM) and glutathione (1 mM). (B) HMW conjugates are not glycosylated because inclusion of peptide N-glycosidase F (PNGF) did not change their mobility. (C) Treatment of protein lysates with DNase (D) but not RNase (R) before
loading the gel significantly reduces the intensity of HMW conjugates. (D) Subcellular fractionation shows that the HMW conjugates are present in both nuclear (N) and crude mitochondrial (M) fractions. (T, total cell lysates; C, cytosol). LaminB was
used as a marker for the nuclear fraction. Results shown are representative of at least three independent experiments.

changes (Fig. 4C). To identify the possible source of DNA,
subcellular fractionation was performed after treatment with
6-OHDA. ERp57 HMW conjugates were enriched in both nuclear and mitochondrial fractions and essentially absent from
cytosolic fractions (Fig. 4D). These data suggest that ERp57
can form HMW complexes with either nuclear or mitochondrial DNA.

lysosomal marker, LAMP1 [Fig. 6A (8)] but not G58 (a golgi
marker), -actin (a cytoskeletal marker), -tubulin (microtubule-organizing center), or 8-hydroxyguanosine (DNA/RNA
oxidative damage marker; not shown). When the percentage of
the cytosolic area stained with LAMP1 is quantified, a significant drug effect is observed (Fig. 6B). These distinctive structural changes are reminiscent of aggresomes (21).

ERp57 forms juxtanuclear clusters after 6-OHDA
treatment in MN9D cells

ERp57 is primarily reduced in
dopaminergic neurons

To identify the location of ERp57 in situ before and after
toxin treatment, cells were fixed and immunostained with antiERp57 antibody. The overall level of ERp57 expression did not
appear to change at 5 h, although its distribution coalesced over
time into a doughnut-shaped structure in the cytosol near the
nucleus (Fig. 5A). Toxin-induced ERp57 clusters co-localized
with cytochrome c (Fig. 5A). Because this timepoint precedes
cytochrome c release from mitochondria (14), these data suggest that mitochondria were also clustering in the juxtanuclear
region. Quantification of cells with ERp57 clusters revealed significantly higher numbers in treated versus nontreated cells 3
and 5 h after 6-OHDA treatment (Fig. 5B). With the same experimental paradigm, toxin-treated ERp57 clusters encircled the

To confirm and extend these results in primary dopaminergic neurons, the redox state of ERp57 in dissociated cultures
was examined. Unlike MN9D cells, primary dopaminergic neurons exhibited a significantly higher level of reduced versus oxidized ERp57 before toxin treatment (Fig. 7A and B). Incubation with 6-OHDA increased oxidized ERp57 monomers,
significantly altering the ratio between reduced and oxidized
ERp57 (Fig. 7B). Co-treatment with NAC prevented these
changes (Fig. 7A and B). Toxin treatment also induced the formation of HMW ERp57 conjugates, albeit to a lesser extent
than those seen in MN9D cells (Fig. 8A). Neither MPP nor
rotenone induced the formation of conjugates (Fig. 8A). Therefore, like MN9D cells, ERp57 specifically responds to 6-OHDA
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FIG. 5. ERp57 forms juxtanuclear clusters after toxin treatment of MN9D cells. (A) ERp57 immunostaining of control
cells reveals a punctuated intracellular distribution that, in most cases, does not overlap with cytochrome c (Cyt c; mitochondria).
After 6-OHDA (75 M) treatment, ERp57 coalesces into doughnut-shaped structures (arrowheads) near the nucleus (N), which
overlap with cytochrome c. (B) Changes in ERp57 distribution were quantified as described in Methods. *p  0.05 by one-way
ANOVA with post hoc Tukey’s test.

although the cellular environment of mesencephalic neurons appears to be less oxidizing.

6-OHDA also leads to ERp57 juxtanuclear
clustering in primary mesencephalic neurons
To determine whether ERp57 formed toxin-induced aggregates, cultures were treated with and without 6-OHDA and
examined for the appearance of clusters. Confocal microscopy
revealed toxin-induced ERp57 juxtanuclear clustering in dopaminergic neurons 6 h after treatment (Fig. 8B). At this time,
many UPR markers have been upregulated as well as showing
early signs of apoptosis (13–15, 25). Thus, the apparent shrinkage of neurons and nuclei (Neu N staining) after toxin treatment was consistent with our previous findings that 6-OHDA–
mediated cell death proceeds via UPR upregulation and downstream apoptosis.

DISCUSSION
A growing body of evidence suggests that ER stress-triggered
UPR is an important component of many neurodegenerative

disorders. Previous results from this laboratory and others have
shown that the parkinsonian mimetic, 6-OHDA, induces UPR
and subsequently apoptosis in the dopaminergic cell line,
MN9D, as well as in primary dopaminergic neurons. Here we
show that one such induced UPR marker, ERp57, rapidly forms
toxin-specific HMW conjugates with DNA as well as juxtanuclear clusters of protein. As both structures form before the induction of apoptosis in these cells (14), these data suggest that
they represent adaptive responses to toxin-mediated UPR.
Although 6-OHDA has been used as a model of PD for over
30 years, its mechanisms of action are still unclear. Readily
autooxidized, 6-OHDA produces many types of ROS, including hydrogen peroxide, superoxide, and quinone derivatives,
which are responsible for its toxicity. Previously we showed
that, before the appearance of UPR markers, 6-OHDA–generated ROS can be rapidly detected in MN9D cells (14) as well
as primary dopaminergic neurons (25). Because ROS formation was quickly followed by the appearance of oxidized proteins and UPR but not release of cytochrome c, these data suggested that death induced by parkinsonian toxins first initiated
ER stress mechanisms and then the mitochondrial apoptotic machinery (14). Surprisingly, obvious oxidation sensors, such as
the ASK1/MAP kinase signaling pathway associated with the
UPR gatekeeper, IRE1 (39), or the mitochondrial permeability

FIG. 6. ERp57 coalesces around LAMP1 after toxin treatment of MN9D cells. (A) ERp57 immunostaining of control cells
is largely independent of LAMP1 (lysosomes). LAMP1 redistributes to the center of the doughnut-shaped structure (arrows). N,
nucleus. (B) When the percentage of the cytosolic area is quantified for LAMP1, a significant drug effect is observed (*p  0.001
by Student’s t test).
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pore, or disruption of ER calcium homeostasis, were not associated with 6-OHDA–mediated cell death [(14), and JSKH, unpublished data). Instead, protein oxidation is one of the first
events after 6-OHDA–generated ROS, in particular, changes in
the protein disulfide isomerase, ERp57, appear early in this process (see Fig. 2). Because ERp57 has been shown to be neuroprotective in models of prion-related disorders (12), its oxidation may trigger downstream sequelae such as UPR and
apoptosis. Whether knockdown or loss of ERp57 accelerates 6OHDA–mediated cell death or its enforced expression blocks
toxin effects remains to be tested in this system.

6-OHDA-induced high-molecular-weight
conjugates of ERp57

FIG. 7. 6-OHDA induces ERp57 oxidation in mesencephalic
neurons. (A) Cells were treated with or without indicated
dose of 6-OHDA for 3 h before NEM alkylation and lysis. Some
samples were pretreated with 5 mM NAC. After AMS treatment, cell lysates were subjected to gradient SDS-PAGE and
Western blotting with antibodies against ERp57. Samples
treated with DTT or DPS for 5 min before fixation were used
to determine the reduced and oxidized states of ERp57 in primary mesencephalic cultures. Nontreated MN9D cell lysates
were included as a reference. (B) Quantitation of results shown
in (A). Values represent mean  SEM, n  3. *p  0.05 by
one-way ANOVA with Tukey’s test.

What is the nature of the HMW conjugates involving ERp57?
As no differences were observed in band intensity when lysates
were treated with a reducing agent before size fractionation and
Western blotting (see Fig. 3B), it seems unlikely that the HMW
species represent covalent interactions stabilized by disulfide
bridges. Numerous studies, however, have shown that reactive
quinone species, such as diethylstilbesterol quinone, 4-hydroxytamoxifen, and/or tocopherol quinine, form covalent quinonelinked bonds with either free sulfhydryl groups or DNA (40,
47). As described, oxidation of 6-OHDA leads to quinone formation (17, 38), as does dopamine itself (41). Inasmuch as H2O2
does not replicate the cell-death paradigms we have observed
(14; this work), we would suggest that it is 6-OHDA–generated
quinone species that are triggering ER stress, UPR, protein carbonylation, etc. (14). In support of this notion, recent data investigating tocopherol quinone toxicity demonstrated a direct
link with ER stress and subsequent cell death (47). These authors suggested that quinone-mediated covalent bonding with
ER PDIs triggered this response (47). Taken together, our data
support a model in which 6-OHDA–generated quinone species
form covalent ERp57/DNA adducts that precede the appearance of ER stress and apoptotic markers.

FIG. 8. 6-OHDA induces HMW conjugates and juxtanuclear clustering of ERp57 in mesencephalic neurons. (A) 6-OHDA
but not MPP or rotenone (Rot) induced HMW ERp57 conjugates in mesencephalic cultures. -actin served as a loading control. *Longer exposure of middle panel. (B) DIV 7 mesencephalic cultures were treated with and without 20 M 6-OHDA for 6
h before fixation. Neuronal and dopaminergic cells were identified with anti-NeuN and anti-TH antibodies, respectively. Toxin
treatment induced the redistribution of ERp57 to a juxtanuclear position. Also at this time, NeuN appears condensed within the
nucleus.
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ERp57 in the nucleus and mitochondria
In general, ERp57 is largely confined to the lumen of the ER,
although detectable levels of expression have been found in the
cytosol and the nucleus (44). Within the ER, ERp57 is thought
to form a non-covalent complex with the lectin-like chaperones,
calreticulin and calnexin, to promote the correct folding of various glycoproteins (48). In the cytosol, ERp57 was identified
as a cytokine-dependent STAT3-associated protein serving as
a chaperone in the transit of STAT3 from the cell membrane
to the nucleus (30). Interestingly, in dopaminergic cells, ERp57
is not abundantly expressed in either the ER or the cytosol.
Rather, the present study demonstrates that ERp57 is highly associated with mitochondrial fractions (see Figs. 3 and 4). More
ERp57 is associated with this fraction than with any other. Further characterization of mitochondrial fractions by using sucrose gradients suggests that ERp57 is most highly enriched in
the mitochondria-associated membrane (MAM) fraction (data
not shown), a region in which the ER membrane is juxtaposed
to the mitochondria. The so-called MAM fraction is responsible for the transport of phospholipids from ER to mitochondria
(42). It will be of interest to test whether ERp57 plays a role
in phospholipid cycling.
In the nucleus, ERp57 catalyzes the attachment of DNA loops
to matrix proteins (6), binds specific DNA sequences associated with, among other things, scaffold/matrix-associated regions (3), and is recruited when various antitumor agents such
as mitomycin C crosslink DNA (2). Mitomycin-induced DNA
damage is thought to be due to its propensity to form highly
reactive quinone derivatives that can alkylate DNA and cross
link individual strands (46). As H2O2 did not induce HMW conjugates of ERp57 (see Fig. 2A), conceivably these can be ascribed to 6-OHDA quinone formation, which has been associated with its cytotoxicity [e.g., (17)]. Therefore, it seems likely
that 6-OHDA not only oxidizes proteins (14) but also damages
DNA, potentially triggering the ERp57 response. In support of
this notion, studies have reported that 6-OHDA produces DNA
adducts and base alterations in cell lines and in vivo (9, 24). It
is unclear, however, what DNA sequences are involved in this
response and how and why mitochondrial DNA is affected as
well. Moreover, it is unclear whether ERp57 is recruited from
the cytosol or from membranous structures. Finally, DNA damage will initiate other adaptive cellular responses, including activation of DNA-repair systems, blockade of cell-cycle progression, transcriptional activation, and when all else fails,
apoptosis. Where in this cascade of events ERp57 plays a role
remains to be determined.
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cient disposal. Surprisingly, we have not observed aggresome
formation in previous studies in either MN9D cells or primary
dopaminergic neurons. Nor did we observe aggresomes when
the major component of Lewy bodies, -synuclein, was overexpressed in either its wild-type or mutant forms (18). Whether
the doughnut-shaped structures (see Fig. 5) formed by ERp57
and cytochrome c are bona fide aggresomes is unclear at present. Several hallmarks of aggresomes are missing, such as clustering around a microtubule-organizing center (data not shown).
However, LAMP1 immunoreactivity at the core of the structure
(see Fig. 6) is suggestive of early accumulation of lysosomes
near the nucleus and the formation of aggresome-like structures.
Many studies have documented the association of chaperones
with protein aggregates. Some of the most compelling evidence
comes from studies showing that HSP70 can overcome many
disease-causing aggregates such as polyglutamine aggregates
or -synuclein aggregates (27). Whether the ERp57-forming
aggregates are derived from the cytoplasm or from recruitment
of mitochondria is unknown. However, it seems reasonable to
suggest that they represent the latter organelle, because so little of this protein is free in the cytosol in dopaminergic cells
(see Fig. 3A). Moreover, the finding that ERp57 staining colocalizes with cytochrome c before its loss from mitochondria
agrees with recent data showing the presence of intact mitochondria in aggresomes (28, 45). Indeed, Waelter et al. (45) hypothesized that mitochondria were recruited into aggresomes to
provide the energy necessary for protein degradation. Results
from this laboratory are consistent with this notion, because the
complex I inhibitor, MPP, does not induce aggresome formation in this system (not shown).
The significance of ERp57 in aggresomes remains unclear.
Although it may simply represent a passively recruited protein,
the formation of HMW conjugates of mitochondrial DNA (see
Fig. 4D) suggests a more active, adaptive response. Taken together, these data suggest that 6-OHDA–generated ROS activates UPR by oxidizing, among other proteins, ERp57. These
changes trigger adaptive cellular responses that, because of prolonged toxin-mediated stress, eventually lead to cell death. Understanding the signaling mechanisms associated with parkinsonian mimetics as well as their temporal induction may aid in
designing better interventions in models of PD.
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ERp57 in aggresomes
A common thread for many neurodegenerative disorders is
the accumulation of misfolded proteins (33). In general, misfolded proteins are handled by the ubiquitin–proteosome system. If overwhelmed, however, ER stress and UPR are triggered.
Similarly, autophagy is also thought to be a cellular defense system. A conceivable point of convergence is suggested by studies showing that if autophagic degradation is not rapid enough
or is insufficient in some way, ER stress and UPR may be initiated. Aggresome formation is thought to contribute to autophagy by concentrating substrates in one area for more effi-

ABBREVIATIONS
6-OHDA, 6-hydroxydopamine; AMS, 4-acetamido-4maleimidylstilbene-2,2-disulfonic acid; DPS, dipyridyl sulfide; DTT, dithiothreitol; ER, endoplasmic reticulum; HMW,
high molecular weight; MAM, mitochondria-associated membrane; MPP, 1-methyl-4-phenylpyridinium; NAC, N-acetylL-cysteine; NEM, N-ethylmaleimide; PBS, phosphate-buffered
saline; PD, Parkinson’s disease; PDI, protein disulfide iso-
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merases; PDIA3, protein disulfide isomerase–associated protein
3; PNGF, peptide:N-glycosidase F; ROS, reactive oxygen
species; Rot, rotenone; TH, tyrosine hydroxylase; UPR, unfolded protein response.
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